SCHEDULE: RTW Investments Updates SAB Biotherapeutics Stake to 3.2%

RTW Investments and Roderick Wong report a 3.2% beneficial ownership stake in SAB Biotherapeutics, Inc., including convertible warrants.

Summary

• RTW Investments, LP and Roderick Wong, M.D. filed an Amendment No. 2 to Schedule 13G for SAB Biotherapeutics, Inc.
• The Reporting Persons beneficially own an aggregate of 1,587,302 shares of SAB Biotherapeutics' Common Stock.
• This ownership represents 3.2% of the class of Common Stock.
• The reported amount includes warrants held by the Reporting Persons to purchase shares of Series A-3 Preferred Stock, which are convertible into 1,587,302 Common Shares.
• The percentage is calculated based on 47,606,851 shares outstanding as of November 10, 2025.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine disclosure of institutional ownership, which provides transparency but does not inherently signal significant positive or negative operational changes for SAB Biotherapeutics.

Future Outlook

No forward-looking statements or guidance regarding SAB Biotherapeutics' operational or financial performance are provided by the Reporting Persons in this filing.

Management Comments

• Roderick Wong, M.D., Managing Partner of RTW Investments, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings provide transparency into institutional investor positions, which can signal confidence or strategic interest in a company within the biotechnology sector. RTW Investments specializes in life sciences, so their stake in SAB Biotherapeutics aligns with their investment focus.

Stakeholder Impact

• Shareholders gain transparency regarding the beneficial ownership stake held by RTW Investments, LP and Roderick Wong, M.D.

Key Dates

Keywords

SAB Biotherapeutics, RTW Investments, Roderick Wong, Schedule 13G, beneficial ownership, common stock, investment adviser, institutional ownership